MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Fate Therapeutics Inc

Cerrado

SectorSanidad

1.13

Resumen

Variación precio

24h

Actual

Mínimo

1.11

Máximo

1.14

Métricas clave

By Trading Economics

Ingresos

15M

-38M

Ventas

-231K

1.6M

Margen de beneficios

-2,309.454

Empleados

181

EBITDA

4.3M

-38M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+332.74% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

8.1M

131M

Apertura anterior

1.13

Cierre anterior

1.13

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

2 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Fate Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 jul 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 jul 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 jul 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 jul 2025, 22:38 UTC

Adquisiciones, fusiones, absorciones

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 jul 2025, 23:44 UTC

Charlas de Mercado

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Fall as Yen Strengthens -- Market Talk

16 jul 2025, 23:24 UTC

Charlas de Mercado

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 jul 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 jul 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Santos Cuts Top End of 2025 Production Guidance

16 jul 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

Santos: Production Recovery Underway in Cooper Basin

16 jul 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 jul 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 jul 2025, 23:16 UTC

Adquisiciones, fusiones, absorciones

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 jul 2025, 23:16 UTC

Adquisiciones, fusiones, absorciones

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 jul 2025, 23:13 UTC

Adquisiciones, fusiones, absorciones

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 jul 2025, 23:13 UTC

Adquisiciones, fusiones, absorciones

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 jul 2025, 23:12 UTC

Adquisiciones, fusiones, absorciones

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 jul 2025, 23:12 UTC

Adquisiciones, fusiones, absorciones

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Free Cash Flow From Operations US$620 Million

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 jul 2025, 22:43 UTC

Charlas de Mercado

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 jul 2025, 22:35 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

16 jul 2025, 22:35 UTC

Charlas de Mercado
Ganancias

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 jul 2025, 22:33 UTC

Charlas de Mercado
Ganancias

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 jul 2025, 22:28 UTC

Charlas de Mercado
Ganancias

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 jul 2025, 22:22 UTC

Charlas de Mercado
Ganancias

Market Talk Roundup: Latest on U.S. Politics

16 jul 2025, 22:22 UTC

Charlas de Mercado
Ganancias

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Comparación entre iguales

Cambio de precio

Fate Therapeutics Inc previsión

Precio Objetivo

By TipRanks

332.74% repunte

Estimación a 12 Meses

Media 4.89 USD  332.74%

Máximo 12 USD

Mínimo 2 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Fate Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

10 ratings

2

Comprar

8

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.9101 / 1.14Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

2 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.